@misc{10481/65578,
year = {2020},
month = {11},
url = {http://hdl.handle.net/10481/65578},
abstract = {Lentiviral vectors (LVs) have gained value over recent years as gene carriers in gene therapy.
These viral vectors are safer than what was previously being used for gene transfer and are capable
of infecting both dividing and nondividing cells with a long-term expression. This characteristic
makes LVs ideal for clinical research, as has been demonstrated with the approval of lentivirus-based
gene therapies from the Food and Drug Administration and the European Agency for Medicine.
A large number of functional lentiviral particles are required for clinical trials, and large-scale
production has been challenging. Therefore, e orts are focused on solving the drawbacks associated
with the production and purification of LVsunder current good manufacturing practice. In recent
years, we have witnessed the development and optimization of new protocols, packaging cell lines,
and culture devices that are very close to reaching the target production level. Here, we review the
most recent, e cient, and promising methods for the clinical-scale production ofLVs.},
organization = {Fundación Empresa Universidad de Granada 	
PR/18/001},
organization = {Instituto de Salud Carlos III

FMM-AP16683-2017},
organization = {Junta de Andalucía

PI-0089-2017},
organization = {Chair "Doctors Galera-Requena in cancer stem cell research"},
organization = {Consejería de Economía, Conocimiento, Empresas y Universidades de la Junta de Andalucía (FEDER Funds) 	
SOMM17/6109/UGR},
publisher = {Mdpi},
keywords = {Lentiviral vector},
keywords = {Gene therapy},
keywords = {Large-scale production},
keywords = {Bioreactor},
title = {Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges},
doi = {10.3390/pharmaceutics12111051},
author = {Martínez Molina, Eduardo and Chocarro Wrona, Carlos and Martínez Moreno, Daniel and Marchal Corrales, Juan Antonio and Boulaiz Tassi, Houria},
}